Where Nrf2 is constitutively hyper-activated in certain cancer phenotypes, such would render these tumours difficult to treat, leading to poor clinical prognosis [32,75,76], while cancers with low Nrf2 activity appear less resistant to chemotherapy and are thus more successfully treated [77]. This evidence concerns the gene NFE2L2 and neoplasm.